TG Therapeutics | TGTX - Loan Capital

Stock Price
32.31
Daily Change
0.10 0.31%
Monthly
22.43%
Yearly
36.04%
Q3 Forecast
31.94

TG Therapeutics reported $245.04M in Loan Capital for its fiscal quarter ending in June of 2025.



Financials
Stock Price USD
Assets USD 702.61M
Cash and Equivalent USD 278.86M
Cost of Sales USD 18.94M
Current Assets USD 663.96M
Current Liabilities USD 171.89M
Debt USD 8.98M
EBIT USD 34.84M
EBITDA USD 12.28M
Employees 338
EPS Earnings Per Share USD 0.17
Equity Capital and Reserves USD 276.43M
Gross Profit on Sales USD 122.21M
Interest Expense on Debt USD 6.72M
Loan Capital USD 245.04M
Market Capitalization USD 4.97B
Net Income USD 28.19M
Operating Expenses USD 106.31M
Operating Profit USD 34.84M
Ordinary Share Capital USD 158.03M
PE Price to Earnings USD 88.77
Pre-Tax Profit USD 30.92M
Sales Revenues USD 141.1M
Selling and Administration Expenses USD 12.04M
Stock USD 155.2M
Trade Creditors USD 134.02M
Trade Debtors USD 231.52M

Loan Capital Change Date
AbbVie USD 64.53B 4.19B Mar/2025
Alaunos Therapeutics USD 0 0 Dec/2024
Amgen USD 53.76B 253M Jun/2025
Ardelyx USD 229.21M 78.36M Jun/2025
Arrowhead Research USD 200.33M 8.59M Jun/2025
Bayer EUR 31.71B 3.31B Jun/2025
Biogen USD 6.28B 1.74B Jun/2025
Corcept Therapeutics USD 0 0 Mar/2025
Dynavax Technologies USD 220.75M 39.75M Jun/2025
Gilead Sciences USD 22.14B 6M Jun/2025
J&J USD 38.36B 7.7B Mar/2025
Novartis USD 24.06B 2.4B Jun/2025
PTC Therapeutics USD 2.13B 1.85B Jun/2025
Regeneron Pharmaceuticals USD 1.99B 719.7M Jun/2025
Roche Holding CHF 32.1B 1.94B Dec/2024
TG Therapeutics USD 245.04M 608K Jun/2025
Vertex Pharmaceuticals USD 112.8M 1.2M Dec/2024